SCHEDULE: Logos Global Discloses 8.9% Passive Stake in iBio

Logos Global Management LP and its affiliates have reported a passive beneficial ownership of 8.9% of iBio, Inc.'s common stock.

Summary

• Logos Global Management LP and its affiliated entities, including Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and William Arsani, have filed a Schedule 13G.
• The filing indicates beneficial ownership of 2,000,000 shares of iBio, Inc. common stock.
• This represents an 8.9% stake in the company, calculated based on 22,487,308 shares outstanding as of November 10, 2025.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iBio, Inc.
• Logos Global Master Fund LP holds the Common Stock for the benefit of its investors.

Sentiment

Score: 7

Explanation: The disclosure of a significant 8.9% passive stake by a reputable institutional investor like Logos Global Management LP is generally viewed positively, indicating confidence in the company's value proposition without implying immediate operational changes or control contests.

Positives

• A significant institutional investor, Logos Global Management LP, has taken an 8.9% passive stake in iBio, Inc.
• This indicates a vote of confidence from a sophisticated investor in iBio's long-term prospects, even if passive.

Negatives

• No direct negatives are presented in this filing, as it is a disclosure of ownership rather than a performance report.

Risks

• The filing itself does not detail specific risks related to iBio's operations or financial health.
• The investment is stated to be passive, meaning the reporting persons do not intend to influence or change control of the issuer.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding iBio, Inc.'s future operations or financial performance, focusing solely on the beneficial ownership stake.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates a significant institutional investment in iBio, Inc., a biotechnology company. Such passive stakes by investment advisors like Logos Global Management LP are common in the industry, signaling investor interest without intent to engage in corporate control battles. It suggests a belief in the company's underlying value or future potential within the biotech sector.

Comparison to Industry Standards

• A passive stake of 8.9% by an institutional investor like Logos Global Management LP is a notable position, often seen as a positive signal in the biotechnology sector, which frequently relies on institutional capital.
• Compared to activist investors who might take similar stakes to push for strategic changes, Logos Global's certification of passive intent aligns with typical investment fund strategies focused on long-term value appreciation rather than immediate operational influence.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the significant passive stake by Logos Global as a positive indicator of investor confidence, potentially leading to increased interest in the stock.
• Management: The passive nature of the investment suggests no immediate pressure or change in strategic direction from this specific shareholder.

Next Steps

• iBio, Inc. will continue its operations as previously planned.
• Logos Global Management LP and its affiliates will continue to hold their passive investment in iBio, Inc.

Key Dates

Recommendation

While the disclosure of a significant passive stake by an institutional investor like Logos Global Management LP can be a positive signal, this Schedule 13G filing itself does not provide new information about iBio's operational performance, financial health, or strategic direction. It merely reports a change in beneficial ownership. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of iBio's business and financial results.

Keywords

iBio Inc, Logos Global Management, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, biotechnology, equity investment